Retrospective Study to Evaluate Probability of MR4 Maintenance Following Frontline Nilotinib Dose De-Escalation after MR4 Achievement in the Patients with Chronic Myeloid Leukemia in Chronic Phase
- Resource Type
- Article
- Authors
- Al-Shaibani, Eshrak; Perusini, Maria Agustina; Lucero, Josephine Anne; Gupta, Gopila; Chiu, May; Gul, Filza; Kim, Dennis D. H.
- Source
- Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p6386-6386, 1p
- Subject
- Language
- ISSN
- 00064971; 15280020
Introduction:Nilotinib (NIL) is a potent second-generation tyrosine kinase inhibitor (TKI) approved for the treatment of newly diagnosed chronic myeloid leukemia (CML) patients (pts) in chronic phase, but reported to increase long-term toxicity such as cardiovascular (CV) risks. The ENESTfreedom study (Leukemia 2021) has reported 55% of treatment-free remission (TFR) rate after front line NIL discontinuation with a median 43.5 months of NIL treatment duration. Question still remains how to improve TFR rate after NIL frontline therapy. A potential solution is dose de-escalation (DESC) after MR4 achievement which could reduce the CV risk while extending MR4 duration prior to TFR attempt, thus increasing the chance of successful TFR attempt.